Literature DB >> 29730444

ARID1A loss in cancer: Towards a mechanistic understanding.

Radhika Mathur1.   

Abstract

Genes encoding subunits of SWI/SNF chromatin remodeling complexes are collectively mutated in 20% of all human cancers. ARID1A is the SWI/SNF subunit gene that is most frequently mutated, at variable frequencies across molecular and histological subtypes of cancer. Mouse modeling has revealed that the role of ARID1A in tumor suppression is highly dependent upon context. Recent mechanistic studies have identified a crucial role for ARID1A in targeting SWI/SNF complexes to tissue-specific enhancers and in maintaining their chromatin accessibility. In the absence of ARID1A, defects in control of enhancer activity impair developmental programs and cause extensive dysregulation of gene expression, thus driving tumor formation. Roles for ARID1A have also been described in other processes linked to tumor suppression including control of the cell cycle/DNA damage checkpoint, regulation of P53 targets, and telomerase activation. Here, we synthesize a mechanistic understanding of the role of ARID1A in tumor suppression and discuss the implications of these new discoveries for therapy.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ARID1A; Cancer; Chromatin remodeling; Enhancers; SWI/SNF

Mesh:

Substances:

Year:  2018        PMID: 29730444     DOI: 10.1016/j.pharmthera.2018.05.001

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  30 in total

1.  Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities.

Authors:  Krystal A Orlando; Vinh Nguyen; Jesse R Raab; Tara Walhart; Bernard E Weissman
Journal:  Expert Rev Anticancer Ther       Date:  2019-05-13       Impact factor: 4.512

2.  GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors.

Authors:  Valentino Clemente; Asumi Hoshino; Mihir Shetty; Andrew Nelson; Britt K Erickson; Ruth Baker; Nathan Rubin; Mahmoud Khalifa; S John Weroha; Emil Lou; Martina Bazzaro
Journal:  Cancer Res Commun       Date:  2022-08-10

3.  RNA Sequencing of Tumor-Educated Platelets Reveals a Three-Gene Diagnostic Signature in Esophageal Squamous Cell Carcinoma.

Authors:  Tiejun Liu; Xin Wang; Wei Guo; Fei Shao; Zitong Li; Yang Zhou; Zhihong Zhao; Liyan Xue; Xiaoli Feng; Yin Li; Fengwei Tan; Kai Zhang; Qi Xue; Shugeng Gao; Yibo Gao; Jie He
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

4.  The impact of ARID1A mutation on molecular characteristics in colorectal cancer.

Authors:  Ryuma Tokunaga; Joanne Xiu; Richard M Goldberg; Philip A Philip; Andreas Seeber; Francesca Battaglin; Hiroyuki Arai; Jae Ho Lo; Madiha Naseem; Alberto Puccini; Martin D Berger; Shivani Soni; Wu Zhang; Sting Chen; Jimmy J Hwang; Anthony F Shields; John L Marshall; Hideo Baba; W Michael Korn; Heinz-Josef Lenz
Journal:  Eur J Cancer       Date:  2020-10-17       Impact factor: 9.162

5.  ARID1A and PGR proteins interact in the endometrium and reveal a positive correlation in endometriosis.

Authors:  Hong Im Kim; Tae Hoon Kim; Jung-Yoon Yoo; Steven L Young; Bruce A Lessey; Bon Jeong Ku; Jae-Wook Jeong
Journal:  Biochem Biophys Res Commun       Date:  2021-03-09       Impact factor: 3.575

6.  Endometrial epithelial ARID1A is critical for uterine gland function in early pregnancy establishment.

Authors:  Ryan M Marquardt; Tae Hoon Kim; Jung-Yoon Yoo; Hanna E Teasley; Asgerally T Fazleabas; Steven L Young; Bruce A Lessey; Ripla Arora; Jae-Wook Jeong
Journal:  FASEB J       Date:  2020-11-22       Impact factor: 5.834

7.  DNA damage-induced activation of ATM promotes β-TRCP-mediated ARID1A ubiquitination and destruction in gastric cancer cells.

Authors:  Zhou-Hua Jiang; Tao Peng; Hai-Long Qian; Cai-de Lu; Feng Qiu; Su-Zhan Zhang
Journal:  Cancer Cell Int       Date:  2019-06-14       Impact factor: 5.722

8.  Clonality of circulating tumor cells in breast cancer brain metastasis patients.

Authors:  Carlotta Riebensahm; Simon A Joosse; Malte Mohme; Annkathrin Hanssen; Jakob Matschke; Yvonne Goy; Isabell Witzel; Katrin Lamszus; Jolanthe Kropidlowski; Cordula Petersen; Anja Kolb-Kokocinski; Sascha Sauer; Kerstin Borgmann; Markus Glatzel; Volkmar Müller; Manfred Westphal; Sabine Riethdorf; Klaus Pantel; Harriet Wikman
Journal:  Breast Cancer Res       Date:  2019-09-03       Impact factor: 6.466

Review 9.  Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity.

Authors:  Pradip De; Nandini Dey
Journal:  Int J Mol Sci       Date:  2019-11-15       Impact factor: 5.923

Review 10.  ARID1A Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms.

Authors:  Shankun Zhao; Youwen Xu; Weizhou Wu; Pan Wang; Yichao Wang; Hao Jiang; Jie Zhu
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.